Obesity and the central nervous system.
Mifflin
Steve W
SW
Strack
Alison
A
D000818:Animals; D019440:Anti-Obesity Agents / Q000494:pharmacology / Q000627:therapeutic use; D002490:Central Nervous System / Q000187:drug effects / Q000378:metabolism* / Q000503:physiopathology; D003510:Cyclohexanes / Q000494:pharmacology / Q000627:therapeutic use; D004734:Energy Metabolism / Q000187:drug effects; D005247:Feeding Behavior; D006801:Humans; D020738:Leptin / Q000378:metabolism; D009765:Obesity / Q000188:drug therapy / Q000378:metabolism* / Q000503:physiopathology; D011720:Pyrazoles / Q000494:pharmacology / Q000627:therapeutic use; D054411:Receptors, Leptin / Q000378:metabolism; D017476:Receptors, Neuropeptide Y / Q000037:antagonists & inhibitors / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D013141:Spiro Compounds / Q000494:pharmacology / Q000627:therapeutic use; D015430:Weight Gain
D019440:Anti-Obesity Agents; D003510:Cyclohexanes; D020738:Leptin; D011720:Pyrazoles; D054411:Receptors, Leptin; D017476:Receptors, Neuropeptide Y; D013141:Spiro Compounds; C100568:neuropeptide Y5 receptor; C515547:spiro(cyclohexane-1,3'(1'H)-furo(3,4-C)pyridine)-4-carboxamide, N-(1-(2-fluorophenyl)-1h-pyrazol-3-yl)-1'-oxo-, trans-